Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Randomized Trial of Irinotecan/Temozolomide With Temsirolimus (NSC# 683864) or Chimeric 14.18 Antibody (Ch14.18) (NSC# 764038) in Children With Refractory, Relapsed or Progressive Neuroblastoma
Brief Summary: This randomized phase II trial studies how well irinotecan hydrochloride and temozolomide with temsirolimus or dinutuximab work in treating younger patients with neuroblastoma that has returned or does not respond to treatment. Drugs used in chemotherapy, such as irinotecan hydrochloride and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as dinutuximab, may find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether giving irinotecan hydrochloride and temozolomide together with temsirolimus or dinutuximab is more effective in treating neuroblastoma.


Options:
A: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Biological: Anti-GD2 antibody | Intervention Type: BIOLOGICAL; Name: Anti-GD2 antibody; Assigned to Arm(s): Group 1
B: Arm Label: Arm I (temozolomide, irinotecan hydrochloride, temsirolimus); Type: EXPERIMENTAL; Interventions: Drug: Irinotecan Hydrochloride, Other: Laboratory Biomarker Analysis, Drug: Temozolomide, Drug: Temsirolimus | Arm Label: Arm II (temozolomide, irinotecan hydrochloride, dinutuximab); Type: EXPERIMENTAL; Interventions: Biological: Dinutuximab, Drug: Irinotecan Hydrochloride, Other: Laboratory Biomarker Analysis, Biological: Sargramostim, Drug: Temozolomide | Intervention Type: BIOLOGICAL; Name: Dinutuximab; Assigned to Arm(s): Arm II (temozolomide, irinotecan hydrochloride, dinutuximab) | Intervention Type: DRUG; Name: Irinotecan Hydrochloride; Assigned to Arm(s): Arm I (temozolomide, irinotecan hydrochloride, temsirolimus), Arm II (temozolomide, irinotecan hydrochloride, dinutuximab) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (temozolomide, irinotecan hydrochloride, temsirolimus), Arm II (temozolomide, irinotecan hydrochloride, dinutuximab) | Intervention Type: BIOLOGICAL; Name: Sargramostim; Assigned to Arm(s): Arm II (temozolomide, irinotecan hydrochloride, dinutuximab) | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Arm I (temozolomide, irinotecan hydrochloride, temsirolimus), Arm II (temozolomide, irinotecan hydrochloride, dinutuximab) | Intervention Type: DRUG; Name: Temsirolimus; Assigned to Arm(s): Arm I (temozolomide, irinotecan hydrochloride, temsirolimus)
C: Arm Label: R0: COJEC plus G-CSF; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Etoposide, Drug: Cisplatin, Drug: Cyclophosphamide, Drug: G-CSF | Arm Label: R0: COJEC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vincristine, Drug: Carboplatin, Drug: Etoposide, Drug: Cisplatin, Drug: Cyclophosphamide | Arm Label: R1: BuMel MAT; Type: ACTIVE_COMPARATOR; Interventions: Drug: Busulfan, Drug: Melphalan | Arm Label: R1: CEM MAT; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Etoposide, Drug: Melphalan | Arm Label: R2: ch14.18/CHO; Type: ACTIVE_COMPARATOR; Interventions: Drug: ch14.18/CHO | Arm Label: R2: ch14.18/CHO plus Aldesleukin; Type: EXPERIMENTAL; Interventions: Drug: Aldesleukin, Drug: ch14.18/CHO | Arm Label: R3: COJEC Induction; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vincristine, Drug: Carboplatin, Drug: Etoposide, Drug: Cisplatin, Drug: Cyclophosphamide | Arm Label: R3: Modified N7; Type: EXPERIMENTAL; Interventions: Drug: Vincristine, Drug: Etoposide, Drug: Cisplatin, Drug: Cyclophosphamide, Drug: Doxorubicin | Arm Label: R4: cnt inf ch14.18/CHO; Type: ACTIVE_COMPARATOR; Interventions: Drug: ch14.18/CHO | Arm Label: R4: cnt inf ch14.18/CHO plus Aldesleukin; Type: EXPERIMENTAL; Interventions: Drug: Aldesleukin, Drug: ch14.18/CHO | Intervention Type: DRUG; Name: Vincristine; Assigned to Arm(s): R0: COJEC, R3: COJEC Induction, R3: Modified N7 | Intervention Type: DRUG; Name: Aldesleukin; Assigned to Arm(s): R2: ch14.18/CHO plus Aldesleukin, R4: cnt inf ch14.18/CHO plus Aldesleukin | Intervention Type: DRUG; Name: ch14.18/CHO; Assigned to Arm(s): R2: ch14.18/CHO, R2: ch14.18/CHO plus Aldesleukin, R4: cnt inf ch14.18/CHO, R4: cnt inf ch14.18/CHO plus Aldesleukin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): R0: COJEC, R0: COJEC plus G-CSF, R1: CEM MAT, R3: COJEC Induction | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): R0: COJEC, R0: COJEC plus G-CSF, R1: CEM MAT, R3: COJEC Induction, R3: Modified N7 | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): R0: COJEC, R0: COJEC plus G-CSF, R3: COJEC Induction, R3: Modified N7 | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): R0: COJEC, R0: COJEC plus G-CSF, R3: COJEC Induction, R3: Modified N7 | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): R3: Modified N7 | Intervention Type: DRUG; Name: G-CSF; Assigned to Arm(s): R0: COJEC plus G-CSF | Intervention Type: DRUG; Name: Busulfan; Assigned to Arm(s): R1: BuMel MAT | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): R1: BuMel MAT, R1: CEM MAT
D: Arm Label: Arm I (isotretinoin) (closed to accrual as of 4/16/2009); Type: ACTIVE_COMPARATOR; Interventions: Drug: Isotretinoin, Other: Laboratory Biomarker Analysis, Other: Pharmacological Study, Other: Quality-of-Life Assessment | Arm Label: Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin); Type: EXPERIMENTAL; Interventions: Biological: Aldesleukin, Biological: Dinutuximab, Drug: Isotretinoin, Other: Laboratory Biomarker Analysis, Other: Pharmacological Study, Other: Quality-of-Life Assessment, Biological: Sargramostim | Intervention Type: BIOLOGICAL; Name: Aldesleukin; Assigned to Arm(s): Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin) | Intervention Type: BIOLOGICAL; Name: Dinutuximab; Assigned to Arm(s): Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin) | Intervention Type: DRUG; Name: Isotretinoin; Assigned to Arm(s): Arm I (isotretinoin) (closed to accrual as of 4/16/2009), Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (isotretinoin) (closed to accrual as of 4/16/2009), Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin) | Intervention Type: OTHER; Name: Pharmacological Study; Assigned to Arm(s): Arm I (isotretinoin) (closed to accrual as of 4/16/2009), Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (isotretinoin) (closed to accrual as of 4/16/2009), Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin) | Intervention Type: BIOLOGICAL; Name: Sargramostim; Assigned to Arm(s): Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin)

Answer: B